Bioavailability Pilot Study of Versus W0035 Versus Stromectol
Status:
Withdrawn
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Ivermectin is prescribed for the treatment of helminthic infections sensitive to ivermectin.
However, it is currently only available as a tablet formulation. W0035 is a powder for oral
suspension of ivermectin developed by PIERRE FABRE DERMATOLOGIE intended to be administered
to children for the treatment of helminthic infections sensitive to ivermectin and mentioned
in the Summary of Product Characteristics (SmPC) of Stromectol.
PIERRE FABRE DERMATOLOGIE intends to carry out this pilot bioavailability study in order to
define the most appropriate formulation to be used in the bioequivalence study.